U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07134088) titled 'A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia' on Aug. 14.

Brief Summary: The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.

Study Start Date: Nov. 21, 2025

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia

Intervention: DRUG: Blinatumomab

Blinatumomab will be administered as a SC injection for up to 5 cycles (each cycle will be 35 days).

Recruitment Status: NOT_YET_...